Our results showed that the broad-spectrum palmitoylation inhibitor 2-BP downregulated palmitoylated STAT3 in colitis cell models, while the selective APT2 inhibitor ML349 upregulated palmitoylated STAT3. Here, LYPLA2 is linked to colitis.